Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2022 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
December 08, 2021 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 24, 2021 18:58 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Targeted in Ransomware Incident

The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations No ransom payments have been made by the Company ROCKVILLE, Md., Nov. 24,...
November 24, 2021 09:12 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas...
November 23, 2021 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements...
November 18, 2021 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Annual Piper Sandler Healthcare Conference

ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 10, 2021 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Upcoming November Investor Conferences

ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 03, 2021 16:01 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Third Quarter 2021 Financial Results

Total revenues for the first nine months of 2021 were $420.7 million; a 12% increase compared to $376.8 million in the first nine months of 2020Third quarter 2021 total revenues were $148.5 million, a...
October 27, 2021 17:42 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
October 20, 2021 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month

Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversityNearly one-in-ten – or 6.1 million children and adolescents...